We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAMYT
RNS Number : 0827N
Amryt Pharma PLC
04 May 2018
4 May 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Posting of Annual Report 2017 and Notice of AGM
Amryt, the biopharmaceutical company focused on rare and orphan diseases, announces that copies of the Annual Report for the year ended 31 December 2017 have today been sent to shareholders along with the Notice of Annual General Meeting ("AGM"). Copies are also available from the Company's website, www.amrytpharma.com.
The AGM will be held at 10am on 5 June 2018 at Holiday Inn London Mayfair, 3 Berkeley Street, Mayfair, London W1J 8NE.
Enquiries:
+353 (1) 518 Amryt Pharma plc 0200 Joe Wiley, CEO Rory Nealon, CFO/COO +44 (0) 20 Shore Capital 7408 4090 Nomad and Joint Broker Edward Mansfield, Mark Percy, Daniel Bush +353 (1) 679 Davy 6363 ESM Adviser and Joint Broker John Frain, Anthony Farrell +44 (0) 20 Stifel 7710 7600 Joint Broker Jonathan Senior, Ben Maddison +44 (0) 20 Consilium Strategic Communications 3709 5700 Financial PR Adviser Amber Fennell Matthew Neal
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSWFIDFASEDI
(END) Dow Jones Newswires
May 04, 2018 02:00 ET (06:00 GMT)
1 Year Amryt Pharma Chart |
1 Month Amryt Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions